E. Katriina Tarkiainen

The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin‐Associated Musculoskeletal Symptoms

Rhonda M. Cooper‐DeHoff, Mikko Niemi, Laura B. Ramsey et al. · Clinical Pharmacology & Therapeutics · 2022 · 296 citations · Full text

Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

E. Katriina Tarkiainen, Janne T. Backman, Mikko Neuvonen et al. · Clinical Pharmacology & Therapeutics · 2012 · 71 citations

Effect of carboxylesterase 1 c.428G &gt; A single nucleotide variation on the pharmacokinetics of quinapril and enalapril

E. Katriina Tarkiainen, Aleksi Tornio, Mikko T. Holmberg et al. · British Journal of Clinical Pharmacology · 2015 · 38 citations · Full text

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions

Helinä Kahma, Anne M. Filppula, Mikko Neuvonen et al. · Drug Metabolism and Disposition · 2017 · 32 citations

<i>CYP3A4*22</i> Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel

Mikko T. Holmberg, Aleksi Tornio, Maria Paile‐Hyvärinen et al. · Clinical Pharmacology & Therapeutics · 2018 · 29 citations